Innate Pharma announces data presentations at upcoming scientific meetings
Innate pharma announces a change to its 2018 financial calendar
Clinical data from ongoing Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) in colorectal cancer patients presented at 2018 ASCO annual meeting
Outcome of Annual General Meeting of May 29, 2018
Preliminary data from a Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients
First quarter 2018 report
Innate Pharma to hold its Annual General Meeting of Shareholders on May 29, 2018 and the release of its Reference document (in french)
Preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN
New preclinical data further support ongoing programs and highlight next generation of immunotherapies
Upcoming investor conferences
